Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis.

OBJECTIVES Although clofazimine has been traditionally used to treat leprosy, there is recent interest in using clofazimine for the treatment of MDR-TB and drug-susceptible TB. However, the mechanisms of resistance to clofazimine are poorly understood. Here, we investigated the molecular basis of clofazimine resistance using resistant mutants isolated in vitro. METHODS We isolated 96 mutants of Mycobacterium tuberculosis resistant to clofazimine and performed WGS and Sanger sequencing to identify possible mutations associated with clofazimine resistance. RESULTS We found that 97% (93/96) of clofazimine-resistant mutants had a mutation in rv0678 encoding a transcription repressor for efflux pump MmpL5. Two mutational hot spots at nucleotide positions 193 and 466 in rv0678 accounted for 43.8% (42/96) and 11.5% (11/96) of the mutations, respectively. The previously reported A202G mutation (S68G) in rv0678 occurred less frequently, in 5 of 96 mutants. The remaining 34 mutations were scattered along the entire rv0678 gene. We discovered two new genes (rv1979c and rv2535c) associated with clofazimine resistance in mutants without rv0678 mutations. CONCLUSIONS Mutations in rv0678 are a major mechanism of clofazimine resistance. Our findings provide useful information for the design of new molecular tests for rapid detection of clofazimine resistance. Further studies are needed to address the role of rv1979c and rv2535c in clofazimine resistance and mechanisms of action.

[1]  Thomas Abeel,et al.  Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance , 2016, Nature Genetics.

[2]  Ying Zhang,et al.  Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[3]  J. Grosset,et al.  Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis , 2015, Proceedings of the National Academy of Sciences.

[4]  G. Bloemberg,et al.  A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment , 2014, European Respiratory Journal.

[5]  B. D. de Jong,et al.  Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline , 2014, PloS one.

[6]  Nitin Kumar,et al.  Crystal Structure of the Transcriptional Regulator Rv0678 of Mycobacterium tuberculosis* , 2014, The Journal of Biological Chemistry.

[7]  S. Cole,et al.  Cross-Resistance between Clofazimine and Bedaquiline through Upregulation of MmpL5 in Mycobacterium tuberculosis , 2014, Antimicrobial Agents and Chemotherapy.

[8]  P. Genevaux,et al.  Multiple Toxin-Antitoxin Systems in Mycobacterium tuberculosis , 2014, Toxins.

[9]  R. Powers,et al.  Metabolomics analysis identifies d-Alanine-d-Alanine ligase as the primary lethal target of d-Cycloserine in mycobacteria. , 2014, Journal of proteome research.

[10]  G. Prosser,et al.  Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in Mycobacterium tuberculosis , 2013, ACS medicinal chemistry letters.

[11]  G. Prosser,et al.  Reinterpreting the Mechanism of Inhibition of Mycobacterium tuberculosisd-Alanine:d-Alanine Ligase by d-Cycloserine , 2013, Biochemistry.

[12]  G. Smith,et al.  Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. , 2013, The New England journal of medicine.

[13]  M. O’Donnell,et al.  Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[14]  N. Ford,et al.  Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. , 2013, The Journal of antimicrobial chemotherapy.

[15]  W. Shi,et al.  Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis , 2013, Emerging Microbes & Infections.

[16]  C. E. J. Rensburg,et al.  are mediated by lysophospholipids. Antimicrobial activities of clofazimine and B669 , 2013 .

[17]  S. Cole,et al.  A Point Mutation in cycA Partially Contributes to the D-cycloserine Resistance Trait of Mycobacterium bovis BCG Vaccine Strains , 2012, PloS one.

[18]  V. Subbulakshmi,et al.  Alanine racemase mutants of Mycobacterium tuberculosis require D-alanine for growth and are defective for survival in macrophages and mice. , 2012, Microbiology.

[19]  H. Steel,et al.  Clofazimine: current status and future prospects. , 2012, The Journal of antimicrobial chemotherapy.

[20]  J. Winkler,et al.  Reduction of Clofazimine by Mycobacterial Type 2 NADH:Quinone Oxidoreductase , 2010, The Journal of Biological Chemistry.

[21]  D. Sherman,et al.  Region of Difference 2 Contributes to Virulence of Mycobacterium tuberculosis , 2010, Infection and Immunity.

[22]  James C. Sacchettini,et al.  Structure of the Mycobacterium tuberculosis d-Alanine:d-Alanine Ligase, a Target of the Antituberculosis Drug d-Cycloserine , 2010, Antimicrobial Agents and Chemotherapy.

[23]  A. Van Deun,et al.  Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. , 2010, American journal of respiratory and critical care medicine.

[24]  Alimuddin Zumla,et al.  Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. , 2010, The Lancet. Infectious diseases.

[25]  K. Kam,et al.  Determination of critical concentrations of second-line anti-tuberculosis drugs with clinical and microbiological relevance. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[26]  Shengyue Wang,et al.  Genetic Basis of Virulence Attenuation Revealed by Comparative Genomic Analysis of Mycobacterium tuberculosis Strain H37Ra versus H37Rv , 2008, PloS one.

[27]  Andreas Burkovski,et al.  A Genomic View of Sugar Transport in Mycobacterium smegmatis and Mycobacterium tuberculosis , 2007, Journal of bacteriology.

[28]  Ying Zhang,et al.  Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA. , 2006, Journal of medical microbiology.

[29]  G. Pósfai,et al.  Characterization of cycA mutants of Escherichia coli. An assay for measuring in vivo mutation rates. , 2006, Mutation research.

[30]  R. Barletta,et al.  Roles of Mycobacterium smegmatisd-Alanine:d-Alanine Ligase and d-Alanine Racemase in the Mechanisms of Action of and Resistance to the Peptidoglycan Inhibitor d-Cycloserine , 2003, Antimicrobial Agents and Chemotherapy.

[31]  D. Mitchison,et al.  The curious characteristics of pyrazinamide: a review. , 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[32]  M. Weinstein,et al.  Susceptibility testing for mycobacteria. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  V. Kapur,et al.  Overexpression of the D-alanine racemase gene confers resistance to D-cycloserine in Mycobacterium smegmatis , 1997, Journal of bacteriology.

[34]  R. Gilman,et al.  Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis , 1997, Antimicrobial agents and chemotherapy.

[35]  M. Lambert,et al.  Mechanism of d-Cycloserine Action: Alanine Racemase from Escherichia coli W , 1972, Journal of bacteriology.

[36]  H. David Resistance to D-cycloserine in the tubercle bacilli: mutation rate and transport of alanine in parental cells and drug-resistant mutants. , 1971, Applied microbiology.

[37]  Browne Sg,et al.  B 663" in the treatment of leprosy. Preliminary report of a pilot trial. , 1962 .

[38]  S. G. Browne,et al.  "B 663" in the treatment of leprosy. Preliminary report of a pilot trial. , 1962, Leprosy review.

[39]  V. Barry,et al.  A New Series of Phenazines (Rimino-Compounds) With High Antituberculosis Activity , 1957, Nature.